GRIT Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 200

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $84.3M

  • Investors
  • 26

GRIT Therapeutics General Information

Description

Developer of cell and gene therapies designed to advance treatment options for cancer and autoimmune diseases through engineered T-cell technologies. The company offers in vivo CAR-T platforms, tumour-infiltrating lymphocyte therapies, gene-editing capabilities, and targeted delivery technologies, enabling healthcare providers and patients with complex immune-related diseases to access scalable and precision-driven immunotherapies.

Contact Information

Formerly Known As
Zhuhai Sand and Gravel Biotechnology Co., Ltd.hai GRIT Biotechnology, Shenzhen GRIT Biotechnology, Shenzhen Sand Gravel Biotechnology, Zhuhai Sand and Gravel Biotechnology
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Building 20, Number 156, Jinghai Fourth Road, Boxing Street
  • Daxing District
  • Beijing, 518055
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Discovery Tools (Healthcare)
Vertical(s)
Corporate Office
  • Building 20, Number 156, Jinghai Fourth Road, Boxing Street
  • Daxing District
  • Beijing, 518055
  • China
+86 021

GRIT Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GRIT Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series C) 09-Oct-2025 $84.3M Completed Generating Revenue
8. Later Stage VC (Series B2) 29-Jul-2025 Completed Generating Revenue
7. Later Stage VC (Series B1) 29-Dec-2024 Completed Generating Revenue
6. Secondary Transaction - Private 25-Oct-2023 Completed Generating Revenue
5. Early Stage VC (Series B) 15-Aug-2023 Completed Generating Revenue
4. Early Stage VC (Series A1) 15-Jul-2021 Completed Generating Revenue
3. Secondary Transaction - Private 16-Mar-2021 Completed Generating Revenue
2. Early Stage VC (Series A) 10-Dec-2020 $15.2M $15.2M Completed Generating Revenue
1. Seed Round 23-Aug-2020 Completed Startup
To view GRIT Therapeutics’s complete valuation and funding history, request access »

GRIT Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of cell and gene therapies designed to advance treatment options for cancer and autoimmune diseases through en
Drug Discovery
Beijing, China
200 As of 2026

Suzhou, China
 

Nanjing, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

GRIT Therapeutics Competitors (47)

One of GRIT Therapeutics’s 47 competitors is CureGenetics, a Venture Capital-Backed company based in Suzhou, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CureGenetics Venture Capital-Backed Suzhou, China
IASO Biotechnology Venture Capital-Backed Nanjing, China
Commense Bio Venture Capital-Backed Boulder, CO
FosunKairos Venture Capital-Backed Shanghai, China
Mabworks Biotech Venture Capital-Backed Beijing, China
You’re viewing 5 of 47 competitors. Get the full list »

GRIT Therapeutics Patents

GRIT Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023197980-A1 Chimeric antigen receptor and use thereof Inactive 11-Apr-2022
US-20250127895-A1 Modified tumor infiltrating lymphocyte and use thereof Pending 29-Jan-2022
WO-2023143515-A1 Modified tumor infiltrating lymphocyte and use thereof Inactive 29-Jan-2022
WO-2023138598-A1 Use of tumor-infiltrating lymphocyte in treatment of diseases Inactive 19-Jan-2022
WO-2023125772-A1 Modified tumor-infiltrating lymphocyte and use thereof Inactive 30-Dec-2021
To view GRIT Therapeutics’s complete patent history, request access »

GRIT Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GRIT Therapeutics Investors (26)

Investor Name Investor Type Holding Investor Since Participating Rounds
Jiangsu Huarui Investment PE/Buyout Minority
Yantai Finance and Investment Development Group Government Minority
Yizhuang Holdings Asset Manager Minority
Beijing Shunxi Private Equity Fund Management Growth/Expansion Minority
Beijing Zhongguancun Capital Fund Management Growth/Expansion Minority
You’re viewing 5 of 26 investors. Get the full list »

GRIT Therapeutics FAQs

  • When was GRIT Therapeutics founded?

    GRIT Therapeutics was founded in 2019.

  • Where is GRIT Therapeutics headquartered?

    GRIT Therapeutics is headquartered in Beijing, China.

  • What is the size of GRIT Therapeutics?

    GRIT Therapeutics has 200 total employees.

  • What industry is GRIT Therapeutics in?

    GRIT Therapeutics’s primary industry is Drug Discovery.

  • Is GRIT Therapeutics a private or public company?

    GRIT Therapeutics is a Private company.

  • What is GRIT Therapeutics’s current revenue?

    The current revenue for GRIT Therapeutics is .

  • How much funding has GRIT Therapeutics raised over time?

    GRIT Therapeutics has raised $208M.

  • Who are GRIT Therapeutics’s investors?

    Jiangsu Huarui Investment, Yantai Finance and Investment Development Group, Yizhuang Holdings, Beijing Shunxi Private Equity Fund Management, and Beijing Zhongguancun Capital Fund Management are 5 of 26 investors who have invested in GRIT Therapeutics.

  • Who are GRIT Therapeutics’s competitors?

    CureGenetics, IASO Biotechnology, Commense Bio, FosunKairos, and Mabworks Biotech are some of the 47 competitors of GRIT Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process